These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 8724049)

  • 1. Interaction between lamivudine (3TC) and other nucleoside analogues for intracellular phosphorylation.
    Veal GJ; Hoggard PG; Barry MG; Khoo S; Back DJ
    AIDS; 1996 May; 10(5):546-8. PubMed ID: 8724049
    [No Abstract]   [Full Text] [Related]  

  • 2. 3TC/AZT: just another combination.
    GMHC Treat Issues; 1995 Dec; 9(12):2. PubMed ID: 11362997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An approach to antiretroviral treatment of HIV disease. Nucleoside monotherapy.
    Gunnarsson G; Hammer SM
    Hosp Pract (1995); 1995 Aug; 30 Suppl 1():5-22. PubMed ID: 7635917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lamivudine (3TC) approved for combination use with AZT.
    James JS
    AIDS Treat News; 1995 Dec; (no 236):1-5. PubMed ID: 11363049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lamivudine (3TC) phosphorylation and drug interactions in vitro.
    Kewn S; Veal GJ; Hoggard PG; Barry MG; Back DJ
    Biochem Pharmacol; 1997 Sep; 54(5):589-95. PubMed ID: 9337075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular metabolism of (-) enantiomeric 2'-deoxy-3'-thiacytidine.
    Cammack N; Rouse P; Marr CL; Reid PJ; Boehme RE; Coates JA; Penn CR; Cameron JM
    Biochem Pharmacol; 1992 May; 43(10):2059-64. PubMed ID: 1318048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.
    Tisdale M; Kemp SD; Parry NR; Larder BA
    Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5653-6. PubMed ID: 7685907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PHS recommends preventive drugs for HIV exposures.
    OR Manager; 1996 Aug; 12(8):1, 6. PubMed ID: 10161372
    [No Abstract]   [Full Text] [Related]  

  • 9. Zidovudine and lamivudine: results of phase III studies.
    Staszewski S
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S57. PubMed ID: 8595510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. North American HIV Working Party.
    Bartlett JA; Benoit SL; Johnson VA; Quinn JB; Sepulveda GE; Ehmann WC; Tsoukas C; Fallon MA; Self PL; Rubin M
    Ann Intern Med; 1996 Aug; 125(3):161-72. PubMed ID: 8686973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New nucleoside analogue, lamivudine, released for HIV therapy.
    Am J Health Syst Pharm; 1996 Jan; 53(2):116. PubMed ID: 8653475
    [No Abstract]   [Full Text] [Related]  

  • 12. In vitro screening of nucleoside analog combinations for potential use in anti-HIV therapy.
    Veal GJ; Barry MG; Khoo SH; Back DJ
    AIDS Res Hum Retroviruses; 1997 Apr; 13(6):481-4. PubMed ID: 9100989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3TC approval may revive AZT's appeal.
    Vazquez E
    Posit Aware; 1996; 7(1):8-9. PubMed ID: 11363136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased zidovudine prescribing associated with lamivudine availability.
    Montaner JS; Hogg RS; Yip B; Gataric N; Schechter MT; O'Shaughnessy MV
    JAMA; 1996 Feb; 275(8):598. PubMed ID: 8594239
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of protease inhibitors on nucleoside analogue phosphorylation in vitro.
    Hoggard PG; Manion V; Barry MG; Back DJ
    Br J Clin Pharmacol; 1998 Feb; 45(2):164-7. PubMed ID: 9491831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy.
    Larder BA; Kemp SD; Harrigan PR
    Science; 1995 Aug; 269(5224):696-9. PubMed ID: 7542804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3TC approved: now for the tough questions.
    Mascolini M
    J Int Assoc Physicians AIDS Care; 1995 Dec; 1(11):6-8. PubMed ID: 11363101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An interview with Charles A.B. Boucher, MD, PhD. Interview by Mark Mascolini.
    Boucher CA
    J Int Assoc Physicians AIDS Care; 1995 Nov; 1(10):30-5. PubMed ID: 11362972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and comparative evaluation of two antiviral agents: beta-L-Fd4C and beta-D-Fd4C.
    Chen SH; Lin S; King I; Spinka T; Dutschman GE; Gullen EA; Cheng YC; Doyle TW
    Bioorg Med Chem Lett; 1998 Nov; 8(22):3245-50. PubMed ID: 9873711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3TC and AZT.
    Treat Rev; 1995; (no 17):2. PubMed ID: 11362294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.